Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (213)	11/17/1998 7:38:00 AM
From: crysball	Respond to of 1386

Stroke Therapy-OP-1 Creative Biomolecules [CBMI] announced preclinical study results which indicate their OP-1 can enhance motor skill recovery up to 3 days following stroke. Their approach is much different [regenerative] than the PARS HU-211 [neuroprotectant], however, HU-211 must be administered within hours of the event, while OP-1 can be administered up to 3 days later. OP-1 has been touted by CBMI to doe everything from grow bone, regenerate kidneys, etc and has not lived up to its promise in actual clinical trials..........in part because a molecule with such an alleged broad spectrum of activity is usually oversold, and its pharmacology is not well understood.

To: Ariella who wrote (213)	11/17/1998 1:57:00 PM
From: Don Walster	Read Replies (2) \| Respond to of 1386

Hi Ariella! Where is everybody? I miss all the great dialogue between you, Yosi s, Gabe Fernandez, David Israel - Rosen and Omer Shvili. Have you guys cooled off on Pharmos? The thing I can't understand is the tremendous decrease in volume. For awhile it was well over a million shares, now it is nothing, a little over 100. Since the predictions are still great, and I hear of no change in the forecast, how do you account for the lack of interest? Kindest regards, Don